search
Back to results

Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos

Primary Purpose

Pediculosis Capitis

Status
Completed
Phase
Phase 2
Locations
Philippines
Study Type
Interventional
Intervention
0.5% Ivermectin lotion
Vehicle
Sponsored by
United Laboratories
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pediculosis Capitis

Eligibility Criteria

3 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Index subjects must have an active lice infestation defined as: At least 3 live lice (adult and/or nymphs) present on the scalp and/or hair as determined by a trained evaluator; After the index subject has been enrolled, additional infested household members will be enrolled.
  • Household subjects must have an active head lice infestation defined as: At least 1 live louse (adult and /or nymph) present on the scalp and/or hair, as determined by a trained evaluator (with the exception of the male head of household who may self- assess, as being lice free).
  • Subject is male or female;
  • Subject is at least 3 years old or older at the time of enrollment;
  • Subject is in good general health based on the medical history;
  • Each adult subject must have an appropriately signed Informed Consent agreement. For children, parents/guardian must sign an Informed Parental Consent agreement for children not old enough to do so. Children of a specified age will be administered a child's assent form
  • The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, they must be willing and able to participate in the study. No more than one working male per household maybe excluded from evaluation if he is assessed as being lice free by himself or the caregiver and cannot come in due to his work schedule. If this individual may have lice, he must come to the test facility, otherwise the entire household will be excluded from study participation.
  • Subject and/or caregiver must be physically able and willing to report to the testing center for the supervised application of the product.
  • Subjects agrees not to use any other form of lice treatment (commercial or mechanical/manual) while participating in the study;
  • Following application and rinsing of the test product, subject agrees not to shampoo / wash, or rinse their hair or scalp until the 24-hour post treatment evaluation has been completed;
  • Subject agrees to not cut or chemically treat their hair while participating in the study;
  • Subject agrees to follow all study instructions.

Exclusion Criteria:

  • History of irritation or sensitivity to ivermectin or lotion components pediculosis or hair care products;
  • Presence of visible skin / scalp conditions that are not attributable to head lice infestation, such as erythema, blisters, vesicles which in the opinion of the investigative personnel will interfere with safety and / or efficacy evaluations;
  • Subjects suffering from psoriasis, atopic dermatitis or other conditions, which in the opinion of the investigator may compromise the objective of the study;
  • Treatment for head lice (OTC, home remedy or Rx) in the last 14 days;
  • Subjects under treatment which in the opinion of the investigator will interfere with the study results;
  • Subjects who participated in a previous investigational drug study within the past 30 days;
  • Subjects who does not understand the requirements for the study participation and/ or likely exhibit poor compliance, in the opinion of the investigator;
  • Females who are pregnant or lactating.
  • Living in a household where at least one member is pregnant, lactating, or planning a pregnancy
  • Subjects with skin lesions, specifically skin breaks are excluded because of possible absorption of the drug

Sites / Locations

  • Clinical Trial Management and Testing Associates, Inc.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

0.5% Ivermectin Lotion

Vehicle control

Arm Description

Outcomes

Primary Outcome Measures

Proportion of participants cured of head lice infestation from their assigned product on day 2, day 8 and day 15 after the first treatment.

Secondary Outcome Measures

Full Information

First Posted
September 14, 2017
Last Updated
March 5, 2018
Sponsor
United Laboratories
search

1. Study Identification

Unique Protocol Identification Number
NCT03286101
Brief Title
Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos
Official Title
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial On The Efficacy And Safety Of Topical 0.5% Ivermectin Lotion For The Treatment Of Head Lice Infestation Among Filipino Children Age 3 Years Or Older
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
September 14, 2017 (Actual)
Primary Completion Date
October 12, 2017 (Actual)
Study Completion Date
November 9, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
United Laboratories

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
This is a randomized, double-blind, placebo-controlled clinical study evaluating the efficacy and safety of a single application of 0.5% ivermectin lotion in Filipino subjects with head lice.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pediculosis Capitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
0.5% Ivermectin Lotion
Arm Type
Experimental
Arm Title
Vehicle control
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
0.5% Ivermectin lotion
Intervention Description
The intervention is composed of a single application of the 0.5% ivermectin lotion.
Intervention Type
Drug
Intervention Name(s)
Vehicle
Intervention Description
The intervention is composed of a single application of the vehicle control.
Primary Outcome Measure Information:
Title
Proportion of participants cured of head lice infestation from their assigned product on day 2, day 8 and day 15 after the first treatment.
Time Frame
Day 2 to day 15 after product application

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Index subjects must have an active lice infestation defined as: At least 3 live lice (adult and/or nymphs) present on the scalp and/or hair as determined by a trained evaluator; After the index subject has been enrolled, additional infested household members will be enrolled. Household subjects must have an active head lice infestation defined as: At least 1 live louse (adult and /or nymph) present on the scalp and/or hair, as determined by a trained evaluator (with the exception of the male head of household who may self- assess, as being lice free). Subject is male or female; Subject is at least 3 years old or older at the time of enrollment; Subject is in good general health based on the medical history; Each adult subject must have an appropriately signed Informed Consent agreement. For children, parents/guardian must sign an Informed Parental Consent agreement for children not old enough to do so. Children of a specified age will be administered a child's assent form The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, they must be willing and able to participate in the study. No more than one working male per household maybe excluded from evaluation if he is assessed as being lice free by himself or the caregiver and cannot come in due to his work schedule. If this individual may have lice, he must come to the test facility, otherwise the entire household will be excluded from study participation. Subject and/or caregiver must be physically able and willing to report to the testing center for the supervised application of the product. Subjects agrees not to use any other form of lice treatment (commercial or mechanical/manual) while participating in the study; Following application and rinsing of the test product, subject agrees not to shampoo / wash, or rinse their hair or scalp until the 24-hour post treatment evaluation has been completed; Subject agrees to not cut or chemically treat their hair while participating in the study; Subject agrees to follow all study instructions. Exclusion Criteria: History of irritation or sensitivity to ivermectin or lotion components pediculosis or hair care products; Presence of visible skin / scalp conditions that are not attributable to head lice infestation, such as erythema, blisters, vesicles which in the opinion of the investigative personnel will interfere with safety and / or efficacy evaluations; Subjects suffering from psoriasis, atopic dermatitis or other conditions, which in the opinion of the investigator may compromise the objective of the study; Treatment for head lice (OTC, home remedy or Rx) in the last 14 days; Subjects under treatment which in the opinion of the investigator will interfere with the study results; Subjects who participated in a previous investigational drug study within the past 30 days; Subjects who does not understand the requirements for the study participation and/ or likely exhibit poor compliance, in the opinion of the investigator; Females who are pregnant or lactating. Living in a household where at least one member is pregnant, lactating, or planning a pregnancy Subjects with skin lesions, specifically skin breaks are excluded because of possible absorption of the drug
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gertrude Chan, M.D.
Organizational Affiliation
Clinical Trial Management and Testing Associates, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Trial Management and Testing Associates, Inc.
City
Muntinlupa
Country
Philippines

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos

We'll reach out to this number within 24 hrs